News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MYMETICS Corporation's Phase Ib Malaria Vaccine: Safe, Well Tolerated and Long-Lasting Antibody Response in Children in Tanzania


6/17/2010 9:00:34 AM

EPALINGES, SWITZERLAND--(Marketwire - June 17, 2010) - Mymetics Corporation, a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that its innovative Malaria vaccine has successfully completed a Phase Ib clinical trial in Tanzania. The study confirms that the company's virosome-based vaccine is well tolerated and safe for adults and children as young as 5 years of age. The vaccine induced specific, long-lasting antibody responses against the key AMA-1 and CSP-1 Malaria antigens in semi-immune subjects, lasting up to 12 months for CSP-1.

Mymetics' Malaria vaccine uses influenza-based virosomes as the antigen carrier -- already approved as a vaccine carrier in more than 40 countries -- with two synthetic peptide vaccine components that mimic the native structure of important antigens found during the key stages in the Malaria parasite's life cycle.

In the Phase Ib trial, conducted in cooperation with the Swiss Tropical and Public Health Institute (Swiss TPH) and Pevion Biotech Ltd., the vaccine was tested during a 12-month period on 40 healthy, semi-immune volunteers (32 children, 8 adults) in Tanzania under endemic conditions. Each subject received two injections that were well tolerated by both adults and children as young as 5 years of age, without any safety issues.

The results showed a high sero-conversion rate for most subjects. The highest percentage of long-lasting sero-converted children following injection of the vaccine was 70% at day 180 for the AMA-1 antigen (against the merozoite), while for the CSP-1 antigen (against the sporozoite) 83% of children were positive for up to 365 days.

"These exciting results are especially promising compared to previous clinical studies, as the group was semi-immune and the trial was carried out without special precautions to avoid parasite exposure -- conditions that normally make it very difficult to trigger a strong immune response," said Professor Marcel Tanner, Director of the Swiss Tropical and Public Health Institute.

"Mymetics' Malaria vaccine is one of only a few that target the blood and liver stages of the Malaria parasite's life cycle, an approach we believe is more likely to achieve efficacy in providing protection and parasitemia control," added Sylvain Fleury, CSO of Mymetics Corporation.

Following this successful Phase Ib trial, Mymetics is now preparing the next phase of development of the multi-stage vaccine with additional promising Malaria antigens. While achieving sterile immunity is the ideal objective, a vaccine that efficiently reduces or controls liver and erythrocyte infection could also reduce parasitemia and symptoms, significantly decreasing mortality and morbidity in children. Mymetics is working closely with not-for-profit organizations to fund these next stages of development.

Mymetics Corporation acquired the Malaria program, including this study, from Pevion Biotech in October 2007. The clinical trial was initially launched by Pevion Biotech Ltd. and the Swiss Tropical and Public Health Institute. The study was performed at the Bagamoyo Research & Training Centre (BRTC) of the Ifakara Health Institute (IHI), Tanzania, under the leadership of Dr. Blaise Genton and Dr. Salim Abdulla.

About Mymetics
Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTCBB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection. Mymetics is led by an international and experienced management team and is supported by a strong Scientific Advisory Board composed of renowned experts. The company has established contacts with world leaders in vaccine development.

Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. The company's HIV vaccine is entering a new proof-of-concept preclinical trial following unprecedented results in a first study, and is also currently in a Phase I clinical trial in human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been successfully completed, while RSV and HSV vaccine candidates are in the preclinical phase. The Influenza vaccine has been out-licensed to Solvay Pharmaceuticals (now Abbott). For further information, please visit www.mymetics.com.

About the Swiss Tropical and Public Health Institute
Founded in 1943, the Swiss Tropical Institute (STI) has become a world-renowned institution for teaching, research and services in the field of International Health Development. In June 2009 the Institute for Social and Preventive Medicine of the University of Basel, internationally recognized in the areas of environmental epidemiology and women's health, was integrated into the STI, and since 2010 the whole institution has publicly taken on a new name, the Swiss Tropical and Public Health Institute, also to be known as the Swiss TPH. Over 500 colleagues from 40 countries work worldwide for the Swiss TPH in research, teaching and service provision, with the single goal to facilitate and contribute to health development worldwide, with a strong focus on underdeveloped countries.

Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.


Contact:
Ronald Kempers
COO
Mymetics Corporation
Tel: +41 21 653 4535

Media:
Christophe Lamps
Senior Partner
Dynamics Group
Mobile: + 41 79 476 26 87
Email: Email Contact

US Media:
Michelle Linn
Linnden Communications
508 362 3087


Read at BioSpace.com

comments powered by Disqus
   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES